Home › Trial NCT06947928
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
- Trial IDNCT06947928
- StatusRecruiting
- PhasePhase 2/3
- Study typeInterventional
- SponsorTuHURA Biosciences, Inc.
- Enrollment118
- Start date2025-12-11
- ConditionsAdvanced Or Metastatic Merkel Cell Carcinoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.